Full Text View
Tabular View
No Study Results Posted
Related Studies
Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)
This study is currently recruiting participants.
Verified February 2009 by Charite University, Berlin, Germany
Study NCT00844142   Information provided by Charite University, Berlin, Germany

First Received on February 12, 2009.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Spondylarthritis
Spondylitis
More general conditions related to this trial
Arthritis
Bone Diseases
Bone Diseases, Infectious
Infection
Joint Diseases
Musculoskeletal Diseases
Spinal Diseases
Interventions listed in this trial
Etanercept 25mg
Sulfasalazine
Additional drug interventions recognized in this trial
TNFR-Fc fusion protein
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Infective Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Charite University, Berlin, Germany
Wyeth is now a wholly owned subsidiary of Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services